Association of CA27.29 and circulating tumor cells before and at different times after adjuvant chemotherapy in patients with early-stage breast cancer: the SUCCESS trial
Background: Evidence for the prognostic value of circulating tumor cells (CTCs) in early-stage breast cancer is swiftly increasing. An alternative approach for identifying patients at risk for recurrence is based on the detection of the mucin-1 (MUC1)-based tumor marker CA27.29. Here we report the a...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 2016
|
| In: |
Anticancer research
Year: 2016, Jahrgang: 36, Heft: 9, Pages: 4771-4776 |
| ISSN: | 1791-7530 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://ar.iiarjournals.org/content/36/9/4771
|
| Verfasserangaben: | Philip Hepp, Ulrich Andergassen, Bernadette Jäger, Elisabeth Trapp, Marianna Alunni-Fabbroni, Thomas W.P. Friedl, Nadeschda Hecker, Ralf Lorenz, Peter Fasching, Andreas Schneeweiss, Tanja Fehm, Wolfgang Janni, Brigitte Rack |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1568100485 | ||
| 003 | DE-627 | ||
| 005 | 20230427155636.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180205s2016 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1568100485 | ||
| 035 | |a (DE-576)498100480 | ||
| 035 | |a (DE-599)BSZ498100480 | ||
| 035 | |a (OCoLC)1340986435 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hepp, Philip |e VerfasserIn |0 (DE-588)1151849502 |0 (DE-627)1012497623 |0 (DE-576)498101142 |4 aut | |
| 245 | 1 | 0 | |a Association of CA27.29 and circulating tumor cells before and at different times after adjuvant chemotherapy in patients with early-stage breast cancer |b the SUCCESS trial |c Philip Hepp, Ulrich Andergassen, Bernadette Jäger, Elisabeth Trapp, Marianna Alunni-Fabbroni, Thomas W.P. Friedl, Nadeschda Hecker, Ralf Lorenz, Peter Fasching, Andreas Schneeweiss, Tanja Fehm, Wolfgang Janni, Brigitte Rack |
| 264 | 1 | |c September 2016 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 05.02.2018 | ||
| 520 | |a Background: Evidence for the prognostic value of circulating tumor cells (CTCs) in early-stage breast cancer is swiftly increasing. An alternative approach for identifying patients at risk for recurrence is based on the detection of the mucin-1 (MUC1)-based tumor marker CA27.29. Here we report the association of these two prognostic markers before and immediately after chemotherapy (CHT), as well as after 2 and 5 years of follow-up. Patients and Methods: The SUCCESS trial compared fluorouracil, epirubicin and cyclophosphamide followed by docetaxel vs. FEC followed by docetaxel plus gemcitabine, and 2 vs. 5 years of treatment with zoledronic acid in 3,754 patients with node-positive or high-risk node-negative early-stage breast cancer. CA27.29 was measured with the ST AIA-PACK CA27.29 reagent (Tosoh Bioscience, Belgium). The cutoff for CA27.29 positivity was >31 U/ml. CTCs were assessed with the CellSearch System (Veridex, USA). The cutoff for CTC positivity was ≥1 CTC/15 ml whole blood. The relationship between CTC positivity and CA27.29 positivity was assessed based on Chi-square statistics and Cramer's V, which varies from 0 (no association between the variables) to 1 (complete association). Samples for CA27.29 and CTC determinations during follow-up were only drawn from patients that had no relapse. Results: Both CA27.29 and CTC data were available for 1,981, 1,602, 1,159 and 707 patients before, immediately after and at 2 and 5 years after CHT, respectively. Positivity rates for CTC were 21.3%, 22.8%, 18.6% and 8.5%, respectively. CA27.29 was positive in 7.9%, 21.0%, 2.8%and 7.5%, respectively. Positivity for both CA27.29 and CTC was found in 2.4%, 4.2%, 0.7% and 1.8% of patients, respectively. The association between CA27.29 and CTC was significant but weak before CHT (p=0.0015; Cramer's V=0.063) and 5 years after CHT (p<0.001; Cramer's V=0.164), and not significant immediately after CHT (p=0.162; Cramer's V=0.035) and 2 years after (p=0.349; Cramer's V=0.028). Conclusion: We showed that CTC and CA27.29 positivity were significantly, but only weakly associated before CHT and 5 years after CHT, while no significant association was found immediately or 2 years after CHT during the course of early-stage breast cancer. It, therefore, seems reasonable to further evaluate the prognostic value of CTCs and CA27.29 as a combined prognostic test of two potentially independent markers that might provide complementary prognostic information. | ||
| 650 | 4 | |a adjuvant | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a minimal residual disease | |
| 650 | 4 | |a Tumor marker | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anticancer research |d Kapandriti, Attiki, Greece : International Institute of Anticancer Research, 2004 |g 36(2016), 9, Seite 4771-4776 |h Online-Ressource |w (DE-627)387478493 |w (DE-600)2145376-7 |w (DE-576)358408717 |x 1791-7530 |7 nnas |a Association of CA27.29 and circulating tumor cells before and at different times after adjuvant chemotherapy in patients with early-stage breast cancer the SUCCESS trial |
| 773 | 1 | 8 | |g volume:36 |g year:2016 |g number:9 |g pages:4771-4776 |g extent:6 |a Association of CA27.29 and circulating tumor cells before and at different times after adjuvant chemotherapy in patients with early-stage breast cancer the SUCCESS trial |
| 856 | 4 | 0 | |u http://ar.iiarjournals.org/content/36/9/4771 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180205 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |e 910000PS109972554 |e 910400PS109972554 |k 0/910000/ |k 1/910000/910400/ |p 10 | ||
| 999 | |a KXP-PPN1568100485 |e 2995316408 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"September 2016"}],"relHost":[{"origin":[{"publisherPlace":"Kapandriti, Attiki, Greece","dateIssuedKey":"2004","dateIssuedDisp":"2004-","publisher":"International Institute of Anticancer Research"}],"id":{"eki":["387478493"],"issn":["1791-7530"],"zdb":["2145376-7"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"international journal of cancer research and treatment","title":"Anticancer research","title_sort":"Anticancer research"}],"recId":"387478493","name":{"displayForm":["International Institute of Anticancer Research"]},"disp":"Association of CA27.29 and circulating tumor cells before and at different times after adjuvant chemotherapy in patients with early-stage breast cancer the SUCCESS trialAnticancer research","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 26.02.13"],"pubHistory":["Nachgewiesen 24.2004 -"],"part":{"issue":"9","extent":"6","pages":"4771-4776","text":"36(2016), 9, Seite 4771-4776","volume":"36","year":"2016"},"language":["eng"]}],"physDesc":[{"extent":"6 S."}],"id":{"eki":["1568100485"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Association of CA27.29 and circulating tumor cells before and at different times after adjuvant chemotherapy in patients with early-stage breast cancer","subtitle":"the SUCCESS trial","title_sort":"Association of CA27.29 and circulating tumor cells before and at different times after adjuvant chemotherapy in patients with early-stage breast cancer"}],"note":["Gesehen am 05.02.2018"],"recId":"1568100485","person":[{"family":"Hepp","role":"aut","given":"Philip","display":"Hepp, Philip"},{"display":"Schneeweiss, Andreas","given":"Andreas","family":"Schneeweiss","role":"aut"}],"language":["eng"],"name":{"displayForm":["Philip Hepp, Ulrich Andergassen, Bernadette Jäger, Elisabeth Trapp, Marianna Alunni-Fabbroni, Thomas W.P. Friedl, Nadeschda Hecker, Ralf Lorenz, Peter Fasching, Andreas Schneeweiss, Tanja Fehm, Wolfgang Janni, Brigitte Rack"]}} | ||
| SRT | |a HEPPPHILIPASSOCIATIO2016 | ||